Angiodynamics Inc (NASDAQ:ANGO) Institutional Investor Sentiment Analysis

AngioDynamics, Inc. (NASDAQ:ANGO) Logo

Sentiment for Angiodynamics Inc (NASDAQ:ANGO)

Angiodynamics Inc (NASDAQ:ANGO) institutional sentiment increased to 1.31 in 2019 Q1. Its up 0.32, from 0.99 in 2018Q4. The ratio improved, as 84 funds opened new or increased equity positions, while 64 cut down and sold equity positions in Angiodynamics Inc. The funds in our partner’s database reported: 36.11 million shares, down from 36.79 million shares in 2018Q4. Also, the number of funds holding Angiodynamics Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 7 Reduced: 57 Increased: 60 New Position: 24.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company has market cap of $698.94 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It has a 11.47 P/E ratio. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

The stock increased 0.27% or $0.05 during the last trading session, reaching $18.75. About 118,506 shares traded. AngioDynamics, Inc. (NASDAQ:ANGO) has declined 3.37% since August 15, 2018 and is downtrending. It has underperformed by 3.37% the S&P500.

Analysts await AngioDynamics, Inc. (NASDAQ:ANGO) to report earnings on September, 26. They expect $0.04 EPS, down 75.00 % or $0.12 from last year’s $0.16 per share. ANGO’s profit will be $1.49 million for 117.19 P/E if the $0.04 EPS becomes a reality. After $0.25 actual EPS reported by AngioDynamics, Inc. for the previous quarter, Wall Street now forecasts -84.00 % negative EPS growth.

Tributary Capital Management Llc holds 1.17% of its portfolio in AngioDynamics, Inc. for 704,499 shares. Thb Asset Management owns 348,541 shares or 1.16% of their US portfolio. Moreover, Perkins Capital Management Inc has 0.69% invested in the company for 45,750 shares. The Wisconsin-based Heartland Advisors Inc has invested 0.55% in the stock. Granahan Investment Management Inc Ma, a Massachusetts-based fund reported 396,140 shares.

More notable recent AngioDynamics, Inc. (NASDAQ:ANGO) news were published by: which released: “AngioDynamics: Stay Away – Seeking Alpha” on January 23, 2018, also with their article: “AngioDynamics’ (ANGO) Q3 Earnings & Revenues Lag Estimates – Nasdaq” published on April 03, 2019, published: “AngioDynamics (ANGO) Down 8.9% Since Last Earnings Report: Can It Rebound? – Nasdaq” on August 09, 2019. More interesting news about AngioDynamics, Inc. (NASDAQ:ANGO) were released by: and their article: “The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial – Benzinga” published on April 02, 2019 as well as‘s news article titled: “AngioDynamics (ANGO) Lags Q4 Earnings Estimates – Nasdaq” with publication date: July 10, 2019.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.